Palopegteriparatide
Protein
Overview
Palopegteriparatide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL5095475).
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Palopegteriparatide expires 12 Nov 2042 and exclusivity 9 Aug 2031. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.